Effect of sarilumab on unacceptable pain and inflammation control in Japanese patients with moderately-to-severely active rheumatoid arthritis: Post hoc analysis of a Phase III study (KAKEHASI).

Tanaka, Yoshiya; Takahashi, Toshiya; van Hoogstraten, Hubert; Kato, Naoto; Kameda, Hideto

Effect of sarilumab on unacceptable pain and inflammation control in Japanese patients with moderately-to-severely active rheumatoid arthritis: Post hoc analysis of a Phase III study (KAKEHASI).

Tanaka, Yoshiya; Takahashi, Toshiya; van Hoogstraten, Hubert; Kato, Naoto; Kameda, Hideto.

Tanaka Y; The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.
Takahashi T; Specialty Care Medical, Sanofi K.K., Tokyo, Japan.
van Hoogstraten H; Medical Affairs, Asahi-Kasei Pharma Corporation, Tokyo, Japan.
Kato N; Global Medical Affairs, Sanofi, Bridgewater, NJ, USA.
Kameda H; Medical Affairs, Asahi-Kasei Pharma Corporation, Tokyo, Japan.

Mod Rheumatol ; 2023 Aug 17.

Article en En | MEDLINE | ID: mdl-37606691